Todd Usen, appointed leader of the Board of Directors last July, visited the Rob Surgical facilities a few weeks ago. During the visit he was able to meet the entire team, attend the live operations carried out by the Bitrack robotic system and work alongside the CEO, Jaume Amat, on the company’s next challenges.

Todd’s collaboration will be essential in the commercialization stage of the Bitrack System open robotic platform, which aims to enter hospitals in 2024 after receiving European certification, which is already in the final phase.

Todd Usen will lead the commercialization project that will allow us to meet the goal of having 50 units of the surgical platform installed in hospitals throughout Europe by 2025, as well as the intensive use of the robot in more than 500 surgeries in the urological field. His contribution and global experience will be key to designing and implementing the installation plan for the first 50 units, as well as offering advice and support to hospital centers that will act as early adopters of Bitrack technology.

During the visit, Todd congratulated the team for their progress and thanked them for their dedication and efforts to universalize the benefits of precision surgery, which will undoubtedly bring benefits to patients, surgeons and hospitals around the world.

“It has been fantastic meeting the team at Rob Surgical. All of them are the reason why I deeply believe in Rob Surgical. I have felt very welcomed and I am looking forward to learning from them and working together.” declared Todd Usen, in an interview that will soon be available on this blog. “I have been absolutely impressed by the capabilities and possibilities of Bitrack. Listening to the surgeons’ feedback after a live operation has been very motivating and confirms the good future prospects.”

It is a privilege to have Todd’s talent, experience, energy and dedication. Todd is a highly respected MedTech executive with extensive experience in growth companies and corporate governance. For the past 25 years, Todd has served as Chairman, Non-Executive Director and CEO leading organizations from technology concept to FDA approval and CE marking.

“Todd is an experienced professional who shares our purpose and values. We look forward to working closely with him to take Rob Surgical to the next level,” highlights Jaume Amat, CEO of Rob Surgical.

This Wednesday, September 20, Jaume Amat, CEO of Rob Surgical, presented the company’s latest news and advances at the Emerging Medtech Summit Europe ’23, placing special emphasis on the final stretch in the certification process.

In the current context, surgical procedures performed by robots only reach 3% of total interventions and each installed robot performs less than one surgery per day. Because of this, only a very limited number of patients benefit from robotic surgery.

Rob Surgical’s system, Bitrack, aims to universalize precision surgery, reaching more patients, facilitating its use and increasing its versatility while reducing costs.

“The atmosphere and activity at the LSI confirms the good moment the sector is experiencing! The mix of already consolidated companies, innovative companies in the growth phase and specialized investors make the LSI the perfect setting and the ideal place to stay up to date and generate value synergies,” declared Jaume Amat.

Bitrack System is the 4-arm surgical robot and on-demand system that allows you to use the robot when you need the robot and switch to manual surgery when necessary. Everything, with maximum agility and speed.

Rob Surgical’s high-precision surgery robot has already been successfully tested with live patients at the Hospital Clínic and European certification will soon be achieved, which will allow production to begin and have 50 robots installed by 2025.

Rob Surgical is in the final approval phase for its surgical robot. It is expected to receive Europe wide certification in mid 2024 and in the USA in mid 2025. Bitrack System, Rob Surgical robot,  is the only 4-arms, open platform, on-demand and accessible robotic solution in the market aimed at giving surgeons open access to patients; for hospitals lower cost and better versatility; and for patients access to benefits of robotic surgeries that are currently only for 2% of cases.

The precision surgery company announced in June that it had successfully performed the first surgeries with its surgical robot in collaboration with Hospital Clínic, the prelude to its certification. Rob Surgical will be  the 8th company to reach CE marking.

Rob Surgical has just incorporated Todd Usen to lead its growth plan. Mr. Usen is a highly respected healthcare executive with extensive experience in scaling and corporate governance. Todd has previously worked as Chairman, Non-Executive Director and CEO leading organizations from technology concept to FDA and CE mark clearance over the last 25 years.

With these milestones achieved, the company confirms its marketing and production plan for 2025, which include the manufacture and installation of 50 units of its surgical platform in hospitals throughout Europe, as well as intensive use of the robot in over 500 surgeries in the urological field, for which the company will have validated the full scope of the interventions. The company, which has raised more than €20 million through different investment rounds, is exploring new partnerships with key partners to achieve its goals by 2025.

On September 18th, the Emerging Medtech Summit Europe ’23 opens in Barcelona, which will take place at the Ritz-Carlton and the Hotel Arts until September 22th.

The event is the epicenter of medical technology and will bring together leaders in medical and health technologies along with investors and entrepreneurs. A top-level congress with the presence of the industry’s top visionaries, opinion leaders and professionals from around the world.

Jaume Amat, CEO of Rob Surgical, will be present at the Panel on Wednesday, September 20th, starting at 4:50 p.m., along with the most influential executives in the world in the MedTech sector. With them we will share the progress of our high-precision open platform, all the milestones achieved so far and the company’s growth plans.

We are proud that Rob Surgical is sharing an event with the great leaders of the industry and eager to learn about the innovations of the best emerging and cutting-edge companies.

Congress days are days of meetings and reunions. Do not hesitate to contact us via LSI’s partnering app or at rss@robsurgical.com.

Check the event agenda by clicking here.